Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis
“Tom co-founded Acceleron in 2003 and has been on the Board from day
Dr. Maniatis is a co-founder, Chief Executive Officer, and Scientific
Director of the New York Genome Center, the Isidore Edelman Professor of
Biochemistry and Molecular Biophysics at the
“Tom truly is a living legend in the life sciences,” said
“It’s been a privilege to be a part of Acceleron from the beginning, helping the company realize the potential of the TGF-beta superfamily in the treatment of blood, musculoskeletal, and fibrotic diseases,” said Dr. Maniatis. “I am especially pleased with the development of luspatercept for the treatment of beta-thalassemia, a longstanding interest of mine since my laboratory cloned and characterized the human beta-globin gene cluster and characterized beta-thalassemia mutations nearly 40 years ago. I look forward to continuing my association with Acceleron in my new role, and focusing on science.”
Luspatercept is an investigational therapy that is not approved for any use in any country.
Luspatercept is a first-in-class erythroid maturation agent that regulates late-stage red blood cell maturation. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. A Phase 3 trial (COMMANDS) in ESA-naïve, lower-risk MDS patients, the BEYOND Phase 2 trial in non-transfusion-dependent beta-thalassemia, and a Phase 2 trial in myelofibrosis are ongoing. For more information, please visit www.clinicaltrials.gov.
Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner,
Acceleron Pharma Inc.
Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
Matt Fearer, (617) 301-9557
Director, Corporate Communications